drugset
drugset / Trial / NCT02254135

Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers

NCT02254135 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Study to investigate safety, tolerability, and pharmacokinetics of single rising peroral doses of BEA 2180 BR

Timeline

Start
2006-12
Primary completion
2007-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BEA 2180 BR Unknown 400 ug Oral
Subject BEA 2180 BR Unknown 800 ug Oral
Subject BEA 2180 BR Unknown 1200 ug Oral

Indications

No indication recorded.